Influence evaluation of pharmaceutical quality control on medication therapy management services by the ECHO model
- VernacularTitle:利用ECHO模型评价药学质控对药物治疗管理服务的影响
- Author:
Kun LIU
1
;
Huanhuan JIANG
1
;
Yushuang LI
1
,
2
;
Yan HUANG
1
;
Qianying ZHANG
1
;
Dong CHEN
3
;
Xiulin GU
4
;
Jinhui FENG
4
;
Zijian WANG
5
;
Yunfei CHEN
6
;
Yajuan QI
7
;
Yanlei GE
8
;
Aishuang FU
8
Author Information
1. Dept. of Pharmacy，North China University of Technology and Science Affiliated Hospital，Hebei Tangshan 063000，China
2. School of Pharmacy，North China University of Technology and Science，Hebei Tangshan 063210，China
3. Dept. of Clinical Nutrition，North China University of Technology and Science Affiliated Hospital，Hebei Tangshan 063000，China
4. Dept. of Pharmacy，the Second Affiliated Hospital of Hebei North University，Hebei Zhangjiakou 075000，China
5. Dept. of Cardiology，the Second Affiliated Hospital of Hebei North University，Hebei Zhangjiakou 075000，China
6. Dept. of Hand Surgery and Anesthesia，the Second Affiliated Hospital of Hebei North University，Hebei Zhangjiakou 075000，China
7. School of Basic Medical Sciences，North China University of Science and Technology，Hebei Tangshan 063210，China
8. Dept. of Respiratory and Critical Care Medicine，North China University of Technology and Science Affiliated Hospital，Hebei Tangshan 063000，China
- Publication Type:Journal Article
- Keywords:
medication therapy management;
pharmaceutical quality control;
ECHO model;
pharmaceutical care
- From:
China Pharmacy
2025;36(9):1123-1128
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To evaluate the influence of pharmaceutical quality control on the efficiency and outcomes of standardized medication therapy management （MTM） services for patients with coronary heart disease by using Economic， Clinical and Humanistic Outcomes （ECHO） model. METHODS This study collected case data of coronary heart disease patients who received MTM services during January-March 2023 （pre-quality control implementation group， n＝96） and June-August 2023 （post-quality control implementation group， n＝164）. Using propensity score matching analysis， 80 patients were selected from each group. The study subsequently compared the economic， clinical， and humanistic outcome indicators of pharmaceutical services between the two matched groups. RESULTS There were no statistically significant differences in baseline data between the two groups after matching （P＞0.05）. Compared with pre-quality control implementation group， the daily treatment cost （16.26 yuan vs. 24.40 yuan， P＜0.001）， cost-effectiveness ratio [23.12 yuan/quality-adjusted life year （QALY） vs. 32.32 yuan/QALY， P＜0.001]， and the incidence of general adverse drug reactions （2.50% vs. 10.00%， P＝0.049） of post-quality control implementation group were decreased significantly； the utility value of the EuroQol Five-Dimensional Questionnaire （0.74± 0.06 vs. 0.71±0.07， P＝0.003）， the reduction in the number of medication related problems （1.0 vs. 0.5， P＜0.001）， the medication adherence score （[ 6.32±0.48） points vs. （6.10±0.37） points， P＝0.001]， and the satisfaction score （[ 92.56±1.52） points vs. （91.95±1.56） points， P＝0.013] all showed significant improvements. Neither group experienced serious adverse drug reactions. There was no statistically significant difference in the incidence of new adverse reactions between the two groups （1.25% vs. 3.75%， P＝0.310）. CONCLUSIONS Pharmaceutical quality control can improve the quality of pharmaceutical care， and the ECHO model can quantitatively evaluate the effect of MTM services， making pharmaceutical care better priced and more adaptable to social needs， thus being worthy of promotion.
